A B S T R A C T To determine the pathogenetic mechanism of a hereditary primary platelet release disorder, arachidonic acid metabolism via the cyclooxygenase pathway was investigated. The propositus' platelets exhibited defective release reaction and secondwave aggregation when stimulated by sodium arachidonate or U46619, a thromboxane A2 (TXA2) agonist. The lack of platelet response to U46619 suggested that the defect was beyond the thromboxane synthetase level. Furthermore, thromboxane B2 (TXB2) formation in the propositus' platelets (558.52 ng/108 platelets) was within the normal range (574.29+SD 27.39 ng/108 platelets) and TXA2 formation appeared to be adequate for aggregating normal platelets. The results were indicative of an abnormal platelet response to TXA2. Failure of the propositus' platelets to aggregate in response to TXA2 formed in normal platelet-rich plasma induced by arachidonate confirmed this notion. To gain further insight, platelet cyclic (c)AMP content was determined. Prostacyclin induced a significant elevation of the propositus' platelet cAMP level comparable to normal values. U46619 suppressed prostaglandin I2-induced cAMP elevation in normal subjects but had no such effect in the patient. We conclude that the primary release disorder observed in this kindred is due to an abnormal platelet response to TXA2 possibly because of TXA2/PGH2 receptor abnormalities.
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METHODS
Patienit. Clinical aind funetionsal abnormalities of this kindred were described (10) . Only the propositus was available for this study. In brief, she w,as a 26-yr-old womiiain with a life-long historv of mild bleeding. She exhibited a prolongecl bleeding time and redltced platelet release reactioni aind second-wave aggregation in respon.se to ADP, collaigeni, aind( epinephrine. Shape chaniige aind primary atggregation in response to ADP were normal. Furthermore, her platelets aggregated normally to thrombin, ionophore A23187, alndl ri stocetin. drawn from an antecuibital vein into p)olypropylene tubes containing one-tenth vol of 3.8% sodituml citrate, mixed a,ndl centrifuged at 200 g for 10 min. Platelet-r-ich plasmia (PRP) was collected and the remiiaininlg sat;mple wNas fturther-centrifuged at 1,000 g for 20 mnm to pr-epitre plattelet-poor plasmaiit.
Platelet concentration of the PRP wats adjusted to 3 x 108/ml with autologous platelet-poor plasma. PRP (0.5 ml) was preincuhated in a cuvette of the Payton duall chaninel aggregometer (Payton Associates, Buffalo, N. Y.) for 1 min and 1 mM sodium arachidonate was added. The mixture was stirred at 37°C for 3 min and then acidified to pH 3.0 with 1 N HCl. TXB2 was extracted with 3 ml ethylacetate twice and dried under nitrogen gas at 50°C. The dried material was reconstituted and applied to a silicic acid columlln (0.5 g/ml) and the TXB2 fraction was collected and dried under nitr-ogeni (1 1). The dried extract was reconstituted in 1 ml of radioimmuniiiiiioassay buffer and assayed according to a previotuslv described radioimmunoassay method (12) . TXB2 recovery was detenrined by adding a known quantity of [1H]TXB2 (New England Nuclear, Boston, Mass.) in a control sample anld the recovery at the end of extraction was calculatedl. The average yield in our laboratory was 80%. The TXB2 radioimmnutinoassay displayed minimal cross-reactivity with other prostaglandclin-type coinpounds and proved to be sensitive to 5 pg per assay tube (12) .
Platelet aggregation study. Platelet iggregation was performed as previously described (13) In brief, 1 mM arachidonate was addedl to 0.5 ml of PRP in a Payton aggregometer. After stirring at 37°C for 30 s, 0.1 ml wasi rapidly transferred to the second( tube that contatined 0.45 ml normal PRP pretreated with a.spirini, and the aggregation wats deterlmined.
Platelet cAMP study. The fuinctionial responsiveness of platelets to TXA2 was investigated by examining their response to U46619, a relatively stable TXA2 agonist. PGI2 stimulates adenylate cyclase, leading to an increase in basal cAMP levels (14) . Since TXA2 or U46619 inhibits PGI2-stimulated cAMP accumulation in normal platelets, we investigated the ability of U46619 to inhibit PGI2-stimulated cAMP in the propositus' platelets. PRP was divided into four 4-ml ali(quots. In aliquot 1, PRP was incubated with U46619 (final concentration 3 ,M) for 90 s at room temperature. 3 nM freshly prepared PGI2 was added and incubated for an additional 90 s. In aliquot 2, PRP was incubated with ethanol for 90 s followed by PGI2 for an additional 90 s. In aliquot 3, PRP was incubated with U46619 for 90 s followed by Tris buffer for an additional 90 s, and in ali(luot 4, PRP was incubated with ethanol for 90 s followed by Tris buffer for an additional 90 s. The mixtures were quickly frozen in liquid nitrogen and stored at -70°C until assay. The samples were kept at -70°C <48 h. The cAMP content in these samples was detenrmined in quadruplicate by the protein binding method of Gilman (15) .
RESULTS
Platelet aggregation in response to sodium arachidonate was completely absent in the propositus (Fig.  1A, B) . These results were suggestive of either cyclooxygenase or thromboxane synthetase deficiency.
However, platelet TXA2 formation in the patient (558.52 ng TXB2/108 platelets) was within the normal range (n = 5, 574.29+4SD 27.39 ng TXB2/108 platelets). Furthermore, U46619, a TXA2 agonist that normally induces maximal aggregation at 4 ,uM, had no apparent effect on the patient's platelets (Fig. IC, D) . These findings led us to postulate that the release defeet was probably due to an abnormial platelet response to TXA2. To test this hypothesis, tranisfer experiments were performed. No aggregation was observed when arachidonate-treated normal PRP was transferred to the patient's platelets. By contrast, transfer of arachidonate-treated patient PRP to normal PRP resulted in platelet aggregation (Fig. IE, F) . These findings indicate that the patient's platelets were in fact capable of synthesizing TXA2 in response to arachidonate, but that they were uinresponsive to the TXA2 that was produced.
To further substantiate the platelet tunresponisiveness to TXA2, the effects of PGI2 an(d U46619 on platelet cAMP levels were investigated. While PGI2 induced a significant elevation of platelet cAMP in the patient, U46619 failed to suppress this incr-ease (Fig. 2) . In contrast, U46619 was capable of suppressing cAMP elevation induced by PGI2 in five normal controls. Although the PGI2-induced cAMP elevation in the patient appears lower than control, it is within two standard deviations of the normal value.
DISCUSSION
It is generally believed that the primaiy release disorder of platelets is related to abnormality of one or more of the enzymes involved in arachidonic acid metabolism. However, the disorder observed in this patient appears to be due to a different mechanism since platelet TXA2 formation in response to arachidonic acid is completely normal. We believe therefore, that the disorder is due to a defect in platelet responsiveness to TXA2. This notion is supported by three lines of evidence. Firstly, the transfer of TXA2 formed in normal PRP failed to elicit platelet aggregation in this patient. Secondly, platelet aggregation in response to U46619, which presumably acts directly on TXA2/ PGH2 receptors (16) , was absent in this patient. Thirdly, U46619 failed to suppress the cAMP elevation induced by PGI2 in this patient, while it was capable of antagonizing the PGI2 effect in normal platelets.
The abnormal platelet responsiveness may be due to a number of mechanisms, notably membrane abnormalities and/or a generalized disturbance in intracellular Ca2+ mobilization. The latter seems unlikely, however, because the patient's platelets respond normally to ionophore A23187 and thrombin, both of which are thought to act through the redistribution of intraplatelet Ca2 . Moreover, the platelets exhibit normal shape change and primary aggregation when stimulated by ADP. Based on these considerations it would appear that the basic defect is most likely related to membrane abnormalities. Since, however, the patient's platelets respond normally to a myriad of aggregating agents with distinctive receptor sites on the platelet membrane, we do not think that there is a (O It Z) PROPOSITUS FIGURE 2 Changes in platelet cAMP content in response to PGI2 and U46619. cAMP was determined in quadruplicate. Five normal subjects were included and each bar represents mean+SD. Basal and U46619-induced platelet cAMP levels of the propositus were comparable to those of normal subjects. The PGI2-induced cAMP level in the patient was slightly below 1 SD but within 2 SD of the normal value. Pretreatment of patient's platelets with U46619 failed to suppress PGI2-induced cAMP elevation. n = 5.
global membrane defect. In view of the fact that the patient's platelets have a subnormal response to TXA2 and its agonist in terms of cAMP suppression and platelet aggregation, we suggest that the defect is due to a specific TXA2/PGH2 receptor abnormality.
